Remikiren (Ro 42-5892) - An orally active renin inhibitor in essential hypertension - Effects on blood pressure and the renin-angiotensin-aldosterone system

American Journal of Hypertension

Volumn 9, Issue 6, 1996, Pages 517-522

  Himmelmann, Anders ^a   Bergbrant, Anders ^b   Svensson, Anders ^b   Hansson, Lennart ^b   Aurell, Mattias ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Blood pressure; Hydrochlorothiazide; Hypertension; Remikiren (Ro 42 5892); Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN; HYDROCHLOROTHIAZIDE; NEW DRUG; PLACEBO; REMIKIREN; RENIN INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030176075     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/0895-7061(95)00340-1     Document Type: Article

References (24)

1. 1. Laragh JH, Sealey JE: The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1990, pp 1329-1348.
2. 2. Hansson L, Dahlöf B, Himmelmann A, Svensson A: Angiotensin-converting enzyme inhibitors in the treatment of essential hypertension, in Robertson JIS, Nicholls MG (eds): The Renin-Angiotensin System. Gower Medical Publishing, London, 1993, pp 91.1-91.24.
3. 3. Lonn EM, Yusuf S, Jha P, et al: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2068.
4. 4. Greenwald L, Becker RC: Expanding paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. Am Heart J 1994;128:997-1009.
5. 5. Karlberg BE: Cough and inhibition of the renin-angiotensin system. J Hypertens 1993;11 (suppl 3):S49-S52.
6. 6. Hedner T, Samuelsson O, Lunde H, et al: Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. Br Med J 1992;304:941-946.
7. 7. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242.
8. 8. Cody RJ: The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994;47:586-598.
9. 9. Burnier M, Waeber B, Brunner HR: Renin inhibitors, angiotensin II antagonists and neutral endopeptidase inhibitors, in Swales JD (ed): Textbook of Hypertension. Blackwell Scientific Publications, Oxford, 1994, pp 1128-1141.
10. 10. Corvol P, Chavuveau D, Jeunemaître X, Ménard J. Human renin inhibitor peptides. Hypertension 1990;16:1-11.
11. 11. Hui KY, Haber E. Renin inhibitors, in Robertson JIS, Nicholls MG (eds): The Renin-Angiotensin System. Gower Medical Publishing, London, 1993, pp 85.1-85.14.
12. 12. Kleinbloesem CH, Weber C, Fahrner E, et al: Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther 1993;53:585-592.
13. 13. MacFadyen RJ, Jones RC, Doig JK, et al: Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. J Cardiovasc Pharmacol 1995;25:347-353.
14. 14. Andersson O, Berglund G, Hansson L, et al: Organization and efficacy of an out-patient hypertension clinic. Acta Med Scand 1978;203:391-398.
15. 15. Dahlöf B: Structural cardiovascular changes in essential hypertension. Studies on the effects of antihypertensive therapy. Blood Pressure 1992;1(suppl 6):1-75.
16. 16. Johnston CI. Angiotensin converting enzyme inhibition, in Doyle A (ed): Handbook of Hypertension, Vol 11: Clinical Pharmacology of Antihypertensive Drugs. Elsevier, Amsterdam, 1988, pp 301-326.
17. 17. Nelson EB, Harm SC, Goldberg M, et al: Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonist, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management. Second Edition. Raven Press, New York, 1995, pp 2895-2916.
18. 18. Pool JL, Gennari J, Goldstein R, et al: Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987;9(suppl 3):S36-S42.
19. 19. Timmermans PBMWM, Wong PC, Chin AT, et al: Angiotensin II receptors and angiotensin II receptor antagonists. Pharm Rev 1993;46:205-225.
20. 20. Camenzind E, Nussberger J, Juillerat L, et al: Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 1991;18:299-307.
21. 21. van den Meiracker AH, Admiraal PJJ, Man int Veld AJ, et al: Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. Br Med J 1990;301:205-210.
22. 22. Kobrin I, Viskoper RJ, Laszt A, et al: Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens 1994;6:349-356.
23. 23. Viskoper RJ, Charlton V, Laszt A, et al: Time dependency of the antihypertensive efficacy of the new renin inhibitor Ro 42-5892. J Hum Hypertens 1994;8:133-136.
24. 24. Derkx FHM, van den Meiracker AH, Fischli W, et al: Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artifact. Am J Hypertens 1991;4:602-609.